Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1963 1
1965 4
1980 1
1981 2
1982 1
1983 3
1984 4
1985 3
1986 1
1987 1
1988 1
1989 3
1990 5
1991 4
1992 1
1993 6
1994 12
1995 4
1996 8
1997 9
1998 14
1999 13
2000 15
2001 13
2002 17
2003 32
2004 31
2005 46
2006 30
2007 66
2008 82
2009 70
2010 84
2011 89
2012 94
2013 88
2014 120
2015 114
2016 134
2017 152
2018 141
2019 143
2020 167
2021 171
2022 206
2023 194
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

2,178 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Spigel DR, et al. Among authors: wu yl. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2. J Clin Oncol. 2022. PMID: 35108059 Free PMC article. Clinical Trial.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Herbst RS, et al. Among authors: wu yl. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. J Clin Oncol. 2023. PMID: 36720083 Free PMC article. Clinical Trial.
The complement system and human autoimmune diseases.
Coss SL, Zhou D, Chua GT, Aziz RA, Hoffman RP, Wu YL, Ardoin SP, Atkinson JP, Yu CY. Coss SL, et al. Among authors: wu yl. J Autoimmun. 2023 May;137:102979. doi: 10.1016/j.jaut.2022.102979. Epub 2022 Dec 18. J Autoimmun. 2023. PMID: 36535812 Free article. Review.
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study.
Wang HM, Zhang CY, Peng KC, Chen ZX, Su JW, Li YF, Li WF, Gao QY, Zhang SL, Chen YQ, Zhou Q, Xu C, Xu CR, Wang Z, Su J, Yan HH, Zhang XC, Chen HJ, Wu YL, Yang JJ. Wang HM, et al. Among authors: wu yl. Cell Rep Med. 2023 Feb 21;4(2):100911. doi: 10.1016/j.xcrm.2022.100911. Epub 2023 Jan 18. Cell Rep Med. 2023. PMID: 36657446 Free PMC article.
Perioperative targeted therapy for oncogene-driven NSCLC.
Liu SY, Zhang JT, Zeng KH, Wu YL. Liu SY, et al. Among authors: wu yl. Lung Cancer. 2022 Oct;172:160-169. doi: 10.1016/j.lungcan.2022.05.007. Epub 2022 May 21. Lung Cancer. 2022. PMID: 35644704 Review.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: wu yl. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. Among authors: wu yl. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
BCAA-BCKA axis regulates WAT browning through acetylation of PRDM16.
Ma QX, Zhu WY, Lu XC, Jiang D, Xu F, Li JT, Zhang L, Wu YL, Chen ZJ, Yin M, Huang HY, Lei QY. Ma QX, et al. Among authors: wu yl. Nat Metab. 2022 Jan;4(1):106-122. doi: 10.1038/s42255-021-00520-6. Epub 2022 Jan 24. Nat Metab. 2022. PMID: 35075301
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, Srimuninnimit V, Bondarenko I, Kubota K, Mukherjee R, Lin J, Souza F, Mok TSK, Cho BC. de Castro G Jr, et al. Among authors: wu yl. J Clin Oncol. 2023 Apr 10;41(11):1986-1991. doi: 10.1200/JCO.21.02885. Epub 2022 Oct 28. J Clin Oncol. 2023. PMID: 36306479 Free PMC article. Clinical Trial.
2,178 results